We are developing a portfolio of inhalation devices which are available to license.
Pressurised Metered Dose Inhalers (pMDI) are ubiquitous and are here to stay. We have applied 21st Century engineering techniques to bring the humble press-and-breathe device up to date with a high-clarity, front-mounted, low-cost dose-counter, and a contemporary design.
Our Breath-actuated Inhaler (BAI) builds on the features of the press-and-breathe device, but is easier to use; patients simply Open-Inhale-Close.
We have complete control over critical device parameters, including resistance and trigger-flow-rate, enabling us to tune the device to specific therapeutic needs.
Our pre-metered dry powder inhaler (DPI) platform can accommodate multiple formulations, separately or in combination. It has an Open-Inhale-Close user-interface and a high-clarity dose-counter.
Further details will be released soon.
We have deep knowledge of inhalers, garnered from years of developing inhalation products and analysing existing devices. The platforms we have chosen to develop have an established market need. Our scientific approach to development ensures that the needs of all stakeholders are demonstrably met, resulting in simple-to-use, reliable, low-cost inhalers for global regulated markets.